Following

1. 1

   CDE accepted a new drug application for injectable recombinant botulinum toxin type A, acceptance number CXSL2601173.

   China · Botulinum toxin type A · Notice1 source
   中1 source

   NMPA Center for Drug Evaluation published the acceptance on 2026-10-27, acceptance number CXSL2601173.1The accepted product is injectable recombinant botulinum toxin type A (Sf9 cells, 150 kD natural amino acid sequence), classified as a new drug.1

   中中国1

   2 of 2 pieces of evidence backed by a source
2. 2

   Aimeike, Huadong Medicine, Langzi, Jinbo and Bloomage all released their 2026 third-quarter reports.

   China · Filing5 sources
3. 3

   Aimeike announced waiving its right of first refusal on a controlling subsidiary's equity transfer, a related-party transaction.

   China · Filing2 sources
4. 4

   Jinbo disclosed its listing announcement for a targeted share issuance and arrangements for the raised funds.

   China · Filing4 sources
5. 5

   Sisram Medical announced renewal of continuing connected transactions and issued an extraordinary general meeting notice.

   China · Filing3 sources

Written from last week's changes every Monday at 08:00 (Beijing). Only what is in our sources; numbers as in the original.